Lasolvan® Rhino (tramazoline) nasal spray 10 ml

indications for Lasolvan® Rhino

Pharmacodynamics Lasolvan® Rhino:

Ambroxol - the active ingredient of the drug Lazolvan increases the secretion of mucus in the respiratory tract. Ambroxol enhances the synthesis of pulmonary surfactant and stimulates ciliary activity. These effects lead to improved mucus separation and excretion (mucociliary clearance). Activating fluid secretion and increasing mucociliary clearance facilitate mucus excretion and reduce coughing.

In vitro studies have shown that the drug Lasolvan reduces the amount of cytokines, as well as the number of tissue-bound mononuclear cells and polymorphonuclear cells.

Pharmacokinetics Lasolvan® Rhino:

Ambroxol binds to plasma proteins approximately 90% in adults and 60–70% in newborns. Ambroxol crosses the placental barrier and reaches the fetal lungs. A large volume of distribution of 6–7 l / kg indicates an accumulation of the substance in the tissues; compared with the content in the blood plasma, the concentration in the lung tissue exceeds the corresponding indicator in the blood plasma by a factor of 17.

Studies with human hepatic microsomes have shown that CYP 3A4 is the dominant isoenzyme responsible for the metabolism of ambroxol . Consequently, ambroxol is mainly metabolized in the liver by phase II of metabolism (to glucuronides) and is degraded to dibromantranylic acid (8-10% of the dose), with the exception of a few minor metabolites. All these metabolites (80–90%) are excreted in the urine. 4.6% of the intravenous dose of the drug is determined as the active substance in the urine, while the conjugated metabolite in the urine is 35.6% of the dose.

The half-life of ambroxol from blood plasma is 10 hours.
In newborns, after repeated intravenous administration, the elimination half-life is approximately 2 times increased due to reduced clearance.

Indications Lasolvan® Rhino:

Treatment of respiratory distress syndrome in preterm and newborn infants.

Application Lasolvan Rino:

The daily dose is 30 mg / kg of body weight, divided into 4 injections per day.

The solution should be administered intravenously slowly, the duration of the infusion is at least 5 minutes using an infusion pump.

The solution can also be prescribed as a drop infusion with 5% glucose solution , 5% levulose solution , 0.9% sodium chloride solution or Ringer's solution. Pp Mucosolvan not be mixed with other p-ramie, pH exceeds 6.3 as possible loss of free Mucosolvan a precipitate due to an increase in pH.

Contraindications Lasolvan® Rhino:

Hypersensitivity to ambroxol or other components of the drug.

Side effects Lasolvan® Rhino:

Lasolvan is generally well tolerated.
Gastrointestinal disorders: mild manifestations of heartburn, dyspepsia, nausea, vomiting, diarrhea.
Immune system, skin and subcutaneous tissue disorders: skin rash, urticaria, angioedema, anaphylactic reactions (including anaphylactic shock) and other allergic reactions.

Special instructions Lasolvan® Rhino:

The sodium concentration in one recommended dose is less than 1 mmol (23 mg).

Very rarely, severe skin lesions have been reported - Stevens-Johnson and Lyell syndromes, temporarily associated with the use of mucolytic agents such as ambroxol . Basically, their appearance could be explained by the severity of the underlying disease or the intake of concomitant medications.

In case of severe damage to the skin or mucous membranes, therapy should be reviewed immediately and the use of Ambroxol should be discontinued .

Interactions
As a result of the use of ambroxol, the concentration of antibiotics (amoxicillin, cefuroxime , erythromycin) in bronchopulmonary secretions and sputum increases.
There are no reports of pharmacological and clinical interactions with other medicinal products.

Overdose Lasolvan® Rhino:

There are no reports of overdose symptoms. In the event of such symptoms, symptomatic treatment is necessary.
Lasolvan